Pfizer defies expectations with a surprising fourth-quarter profit, despite a downturn in its Covid-related business. The analysis covers the reduced impact of returned Paxlovid doses on revenue, the surpassing of predicted sales for Pfizer’s Covid vaccine, and strategic initiatives like cost-cutting and the acquisition of Seagen. It concludes with a review of Pfizer’s stock market performance, reflecting investor responses to these developments. Find out more on FinanceVoyager